Form 4: Disc Medicine Director Sells 99,000 Shares

Disc Medicine Director Kevin Bitterman reported the sale of 99,000 shares of common stock over two days in October 2025.

Summary

• Kevin Bitterman, a Director of Disc Medicine, Inc. (IRON), reported the sale of 99,000 shares of common stock.
• The sales occurred on October 7 and October 8, 2025, and were executed under a Rule 10b5-1 plan.
• Shares were sold at weighted average prices ranging from $68.01 to $72.39 per share.
• Following these transactions, Bitterman's indirect beneficial ownership stands at 972,170 shares across Atlas Venture Opportunity Fund I, LP, Atlas Venture Opportunity Fund II, LP, and Atlas Venture Fund XII, L.P.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant insider selling by a director, which can signal a lack of confidence or belief that the stock is fully valued, despite the sales being under a 10b5-1 plan.

Negatives

• A Director sold a significant number of shares (99,000 shares) over two days.
• Insider selling can be perceived negatively by the market, potentially signaling a lack of confidence or a belief that the stock is fully valued.

Risks

• Potential negative investor sentiment due to significant insider selling by a director.
• Market perception that the stock may be overvalued if a director is divesting a substantial portion of their holdings.

Future Outlook

NA

Industry Context

Insider selling is a common occurrence, often for personal liquidity or portfolio rebalancing, but can also be interpreted by the market as a signal regarding the company's future prospects or valuation. The sales were conducted under a Rule 10b5-1 plan, which indicates a pre-arranged trading plan set up when the insider was not in possession of material non-public information.

Stakeholder Impact

• Shareholders may interpret the insider selling as a negative signal, potentially impacting investor confidence and the stock price.

Key Dates

Recommendation

While the sale of 99,000 shares by a director is a notable event and can create negative sentiment, the transactions were executed under a Rule 10b5-1 plan, suggesting a pre-scheduled divestment rather than an immediate reaction to new information. The director still retains significant indirect beneficial ownership (972,170 shares). Investors should monitor future insider activity and company performance, but a 'hold' recommendation is appropriate given the context of a pre-arranged sale and continued substantial ownership.

Keywords

Disc Medicine, IRON, Insider Selling, Form 4, Director, Stock Sale, Equity Transaction, Kevin Bitterman, Atlas Venture